Ongoing Clinical Trials for H1N1 Influenza
Two clinical trials are currently investigating treatments for severe H1N1 influenza, focusing on antiviral therapy and supportive medications in hospitalized patients requiring intensive care. These studies are examining how oseltamivir blood levels and the addition of corticosteroids may improve outcomes in critically ill patients with severe flu infections.
Clinical trial locations
- France
- Spain
Study of oseltamivir and paracetamol blood levels in critically ill patients with severe influenza requiring mechanical ventilation
This trial is designed for the most severely ill patients with influenza who require intensive care and breathing support through a ventilator. The main focus is understanding how the amount of oseltamivir, also known by the brand name Tamiflu, in the blood affects recovery outcomes.
Main inclusion criteria: Participants must be adults aged 18 or older with confirmed severe influenza requiring intensive care. They must need breathing support through a tube inserted into the windpipe and have started oseltamivir treatment through a feeding tube within the past 24 hours, with no more than two doses given. Patients must have active social security coverage and provide appropriate consent, either directly or through a support person or family member.
Main exclusion criteria: The trial cannot accept patients who are not in the intensive care unit, those who do not require mechanical ventilation, or anyone under 18 years of age. Patients without confirmed severe influenza infection or those who cannot receive oseltamivir treatment are excluded. Individuals who have been intubated for more than 48 hours before enrollment, pregnant women without specific approval, those with known allergies to the study medication, and participants in other interfering clinical trials cannot join.
Trial focus and goals: The study aims to understand how medication absorption and blood levels affect treatment outcomes in critically ill flu patients. Researchers will measure oseltamivir levels in the blood after 48 hours of treatment and perform a paracetamol absorption test to check how well medications are being absorbed through the digestive system. Blood samples will be taken on days 2, 3, and 5, and throat swabs will be collected on day 5 to measure flu virus levels. The study will track how long patients need breathing support and monitor their recovery over 90 days.
Investigational drug: Oseltamivir is the primary medication being studied. It is an antiviral medication that works by stopping the flu virus from spreading inside the body. In the body, it converts to its active form called oseltamivir carboxylate. The medication is given as 75 mg capsules dissolved and administered through a feeding tube for up to 10 days. This research will help doctors understand if adjusting medicine doses based on blood levels could lead to better treatment outcomes for severely ill flu patients.
Study on the Effects of Dexamethasone and Oseltamivir in Patients with Severe Influenza
This trial compares the use of dexamethasone, a corticosteroid medication, with a placebo in patients receiving oseltamivir for severe influenza. The study aims to determine whether adding dexamethasone to standard flu treatment can improve outcomes for hospitalized patients.
Main inclusion criteria: Participants must be adults aged 18 or older with a confirmed diagnosis of influenza A or B virus infection, verified by antigen test or RT-PCR using a sample from the nose or lungs. They must be hospitalized with an expected stay of more than 24 hours and be currently receiving or starting treatment with oseltamivir. Women who can become pregnant must use contraceptive methods until 30 days after finishing the treatment. All participants must sign an informed consent form agreeing to participate after understanding all study details.
Main exclusion criteria: The trial excludes patients under 18 or over 65 years of age, those who are pregnant or breastfeeding, and anyone with known allergies to oseltamivir or dexamethasone. Patients currently participating in another clinical trial cannot join. Those with a history of severe allergic reactions to any medication, a compromised immune system, or severe liver or kidney disease are excluded. Patients hospitalized for influenza with a status of 3 or higher on the Hospital Recovery Scale, indicating the need for supplemental oxygen or intensive care, cannot participate.
Trial focus and goals: The study will randomly assign participants to receive either dexamethasone combined with oseltamivir or oseltamivir with a placebo. The primary focus is evaluating patients’ recovery status on day 7 after starting treatment using the Hospital Recovery Scale. Additional assessments include measuring clinical stability, hospital stay duration, and any need for intensive care or mechanical ventilation. Follow-up visits will occur at 30 and 90 days after treatment completion to evaluate dependency and frailty levels and understand the long-term impact of the treatment on daily living activities.
Investigational drugs: The trial tests two medications. Dexamethasone is being studied to see if it can help patients with severe influenza recover more quickly by reducing inflammation in the body. It works at the molecular level by binding to glucocorticoid receptors, decreasing the production of substances that cause inflammation. Oseltamivir serves as the standard antiviral treatment given to all patients. It works by inhibiting the neuraminidase enzyme, which is essential for the influenza virus to spread within the body, helping to reduce the severity and duration of flu symptoms.
Summary
These two clinical trials represent current research efforts to improve treatment for patients with severe H1N1 influenza requiring hospitalization. Both studies focus on optimizing the use of oseltamivir, the standard antiviral treatment for influenza, though they approach the question from different angles.
The French trial focuses on the most critically ill patients requiring mechanical ventilation in intensive care units, examining whether measuring and adjusting oseltamivir doses based on blood levels could improve outcomes. This research recognizes that severely ill patients may absorb medications differently than less critical patients.
The Spanish trial takes a different approach by investigating whether adding dexamethasone, an anti-inflammatory medication, to standard oseltamivir treatment can benefit hospitalized patients with severe influenza. This study includes a broader range of hospitalized patients, though it excludes the most severely ill and elderly patients.
Geographically, these trials are being conducted in Western Europe, reflecting ongoing research interest in optimizing treatment for severe influenza across different healthcare systems. Both studies emphasize careful monitoring of patients’ recovery and the importance of understanding how different treatment approaches affect outcomes in severe flu infections.
